Intertwined associations between oxytocin, immune system and major depressive disorder

Jiang, Junliang; Yang, Miaoxian; Tian, Ming; Chen, Zhong; Xiao, Lei; Gong, Yubin

doi:10.1016/j.biopha.2023.114852

Cited by 13 publications

(1 citation statement)

References 200 publications

(263 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oxytocin was thought to be closely related to MDD because of the lower oxytocin level in patients with MDD and those with the oxytocin receptor gene polymorphism. Simultaneously, its use for treatment in patients with MDD has come to the fore because oxytocin modulates the HPA axis and is associated with neurotransmitters such as serotonin 23 . However, there are conflicting results for oxytocin treatment in MDD.…”

Section: Oxytocin For Treating Mood Disordersmentioning

confidence: 99%

Oxytocin in the Treatment of Psychiatric Disorders

KAGIZMAN,

HOCAOGLU

2023

MMJ

View full text Add to dashboard Cite

Oxytocin is a peptide hormone that is most known for its role in reproduction. However, many effects other than reproduction have been defined. The lifetime prevalence of mental disorders is approximately 20%, and they have a significant ratio among the diseases that lead to disability. Treatment resistance may cause the mental disorder to become chronic and increase disability. With the examination of the oxytocinergic system, both the elucidation of the etiology of the diseases and their evaluation as a new treatment option have come to the fore. In various studies, it has been desired to create a more effective treatment model by measuring the level of oxytocin in psychiatric disorders, examining its receptor, and applying exogenous oxytocin in the treatment. In this review, an overview of oxytocin’s efficacy in treatment is presented by considering the relationship between psychiatric disorders and the oxytocinergic system.

show abstract

Section: Oxytocin For Treating Mood Disordersmentioning

confidence: 99%

Oxytocin in the Treatment of Psychiatric Disorders

KAGIZMAN,

HOCAOGLU

2023

MMJ

View full text Add to dashboard Cite

show abstract

Circadian copeptin and oxytocin profiles in anorexia nervosa: Exploring the interplay with neurohypophysis opioid tone

Doua,

Germain,

Merabet

et al. 2024

Euro Eating Disorders Rev

View full text Add to dashboard Cite

ContextNeurohypophysis (NH) function in eating disorders (ED) remains poorly elucidated. Studies on vasopressin and oxytocin display inconclusive findings regarding their levels and associations with psychological complications in ED. The profile of opioid tone, a crucial NH activity regulator, is also unknown.ObjectiveTo characterise the circadian profile of NH hormones and NH opioid tone using positron emission tomography/MRI (PET/MRI) imaging in patients with ED compared to healthy controls.MethodsTwelve‐point plasma circadian profiles of copeptin and oxytocin, alongside nutritional and psychological scores, were assessed in age‐matched female participants: 13 patients with anorexia nervosa restrictive‐type (ANR), 12 patients recovered from AN (ANrec), 14 patients with bulimia nervosa and 12 controls. Neurohypophysis PET/MRI [11C] diprenorphin binding potential (BPND) was evaluated in AN, ANrec and controls.ResultsResults revealed lower copeptin circadian levels in both ANR and ANrec compared to controls, with no oxytocin differences. Bulimia nervosa exhibited elevated copeptin and low oxytocin levels. [11C] diprenorphin pituitary binding was fully localised in NH. Anorexia nervosa restrictive‐type displayed lower NH [11C] diprenorphin BPND (indicating higher opioid tone) and volume than controls. In ANR, copeptin inversely correlated with osmolarity. Neurohypophysis [11C] diprenorphin BPND did not correlated with copeptin or oxytocin.ConclusionCopeptin demonstrated significant group differences, highlighting its potential diagnostic and prognostic value. Oxytocin levels exhibited conflicting results, questioning the reliability of peripheral blood assessment. Increased NH opioid tone in anorexia nervosa may influence the vasopressin or oxytocin release, suggesting potential therapeutic applications.

show abstract